Preventive effects of flavonoid extracts from ilex hainanensis Merr. on rats with hepatic steatosis induced by a high-fat diet

Drug Development Research

Volumn 73, Issue 6, 2012, Pages 308-316

  Wei, Xiang Lan ^a   Chen, Xiao Qing ^b   Fang, Ru Tang ^c   Sun, Xiao Yan ^d   Zhu, Chang Sheng ^a   Yang, Jie ^b   Xue, Xin ^a   Wang, Qiang ^b  

^a Xi'An Chest and Tuberculosis Hospital   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c Department of Gastroenterology   (China)

^d SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

hepatic steatosis; high fat diet; Ilex hainanensis Merr.

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FATTY ACID; FLAVONOID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ILEX HAINANENSIS EXTRACT; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PLANT EXTRACT; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVITY; FATTY LIVER; GLUCOSE BLOOD LEVEL; ILEX HAINANENSIS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIVER HISTOLOGY; LIVER PROTECTION; MALE; MEDICINAL PLANT; NONHUMAN; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84866365058     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21014     Document Type: Article

References (49)

1. Adams LA, Angulo P,. 2005. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 22: 1129-1133. (Pubitemid 41224168)
2. Akbar DH, Kawther AH,. 2003. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: prevalence and general characteristics. Diabetes Care 26: 3351-3352. (Pubitemid 37466902)
3. Angulo P, Lindor KD,. 2002. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol 17 (Suppl.): S186-S190. (Pubitemid 34539308)
4. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G,. 2000. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 45: 1929-1934.
5. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C,. 2000. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132: 112-117. (Pubitemid 30044177)
6. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR,. 1999. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467-2474. (Pubitemid 29420675)
7. Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, Garcia-Urkia N, Sarasqueta C, Cosme A, Irastorza B,. 2008. Gonzalez A and others. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 8: 40.
8. Burt AD, Mutton A, Day CP,. 1998. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 15: 246-258. (Pubitemid 28536758)
9. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, Yueh SK,. 2006. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 40: 745-752.
10. Chen XQ, Zan K, Liu H, Yang J, Lai MX, Wang Q,. 2009a. Triterpenes and flavonoids from Ilex hainanensis Merr. (Aquifoliaceae). Biochem Syst Ecol 37: 678-682.
11. Chen XQ, Zan K, Yang J, Lai MX, Wang Q,. 2009b. A novel flavanone from Ilex hainanensis Merr. Nat Prod Res 23: 442-447.
12. Chinese Pharmacopoeia Committee. 2010. Chinese pharmacopoeia (part1). Beijing: Chemical Industry Press.
13. Chopra M, Fitzsimons PE, Strain JJ, Thurnham DI, Howard AN,. 2000. Nonalcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamin and carotenoid concentrations. Clin Chem 46 (8 Pt. 1): 1162-1170. (Pubitemid 30643320)
14. Clark JM, Brancati FL, Diehl AM,. 2002. Nonalcoholic fatty liver disease. Gastroenterology 122: 1649-1657. (Pubitemid 34533559)
15. Day CP, James OF,. 1998. Steatohepatitis: a tale of two "hits?" Gastroenterology 114: 842-845.
16. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L,. 2004. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 53: 1020-1023. (Pubitemid 38824162)
17. Esterbauer H, Schaur RJ, Zollner H,. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128. (Pubitemid 121003917)
18. Fan JG, Saibara T, Chitturi S, Kim BI, Sung JJ, Chutaputti A,. 2007. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 22: 794-800. (Pubitemid 46911036)
19. Fang RT, Wei TS,. 2011. Preventive effects of extracts from Ilex hainanensis Merr. on rats with experimental hyperlipidemia. Northwest Pharm J 26: 123-125.
20. Farrell GC, Larter CZ,. 2006. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 (Suppl. 1): S99-S112.
21. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ,. 2004. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40: 185-194. (Pubitemid 38868937)
22. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J, Kerr DJ,. 1996. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 2: 659-668. (Pubitemid 26133468)
23. Giannini EG, Testa R, Savarino V,. 2005. Liver enzyme alteration: a guide for clinicians. CMAJ 172: 367-379. (Pubitemid 40208726)
24. Grattagliano I, Portincasa P, Palmieri VO, Palasciano G,. 2007. Managing nonalcoholic fatty liver disease: recommendations for family physicians. Can Fam Physician 53: 857-863. (Pubitemid 47164278)
25. Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa,. 2004. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 19: 854-858. (Pubitemid 39093200)
26. Halliwell B,. 1994. Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? Lancet 344: 721-724.
27. Hayek T, Fuhrman B, Vaya J, Rosenblat M, Belinky P, Coleman R, Elis A, Aviram M,. 1997. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 17: 2744-2752. (Pubitemid 28016017)
28. Hong XZ, Li LD, Wu LM,. 2007. Effects of fenofibrate and Xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 34: 27-35. (Pubitemid 46069582)
29. Hotamisligil GS,. 1999. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 245: 621-625. (Pubitemid 29278870)
30. James O, Day C,. 1999. Non-alcoholic steatohepatitis: another disease of affluence. Lancet 353: 1634-1636. (Pubitemid 29224514)
31. Kondo K, Hirano R, Matsumoto A, Igarashi O, Itakura H,. 1996. Inhibition of LDL oxidation by cocoa. Lancet 348: 1514.
32. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ,. 2003. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38: 413-419. (Pubitemid 36919862)
33. Li GW, Hu YH, Yang WY, Jiang YY, Cao HB, Wang JP, Xiao JZ, Hu ZX, Pan XR,. 1998. Effects of insulin resistance and insulin secretion on the development of type II diabetes mellitus. Chin J Intern Med 37: 24-28.
34. Marchesini G, Marzocchi R, Agostini F, Bugianesi E,. 2005. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16: 421-427. (Pubitemid 41017626)
35. Mazur A, Bayle D, Lab C, Rock E, Rayssiguier Y,. 1999. Inhibitory effect of procyanidin-rich extracts on LDL oxidation in vitro. Atherosclerosis 145: 421-422. (Pubitemid 29359154)
36. McCullough AJ,. 2004. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8: 521-533, viii. (Pubitemid 39141140)
37. Morris AA,. 1999. Mitochondrial respiratory chain disorders and the liver. Liver 19: 357-368. (Pubitemid 29457212)
38. Nagarajan P, Mahesh KM, Venkatesan R, Majundar SS, Juyal RC,. 2012. Genetically modified mouse models for the study of nonalcoholic fatty liver disease. World J Gastroenterol 18: 1141-1153.
39. Neuschwander-Tetri BA,. 2005. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 330: 326-335. (Pubitemid 41831904)
40. Neuschwander-Tetri BA, Caldwell SH,. 2003. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219. (Pubitemid 36538699)
41. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van, Norren K, van, Leeuwen PA,. 2001. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 74: 418-425. (Pubitemid 32880250)
42. Qin Y, Tian YP,. 2010. Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Lipids Health Dis 9: 78.
43. Sabir N, Sermez Y, Kazil S, Zencir M,. 2001. Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Eur J Ultrasound 14: 121-128. (Pubitemid 33026505)
44. Shang J, Chen LL, Xiao FX, Sun H, Ding HC, Xiao H,. 2008. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol Sin 29: 698-706. (Pubitemid 351799479)
45. Shen L, Fan JG, Shao Y, Zeng MD, Wang JR, Luo GH, Li JQ, Chen SY,. 2003. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol 9: 1106-1110. (Pubitemid 36681689)
46. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Pichiri I, Sorgato C, Zenari L, Bonora E,. 2010. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 53: 713-718.
47. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y, et al. 2006. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut 55: 415-424. (Pubitemid 43268283)
48. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG,. 2001. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48: 206-211. (Pubitemid 32141844)
49. Wullaert A, van Loo G, Heyninck K, Beyaert R,. 2007. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev 28: 365-386. (Pubitemid 46984825)